News: Skin Cancer

Next Page »

NCI report shows U.S. cancer deaths on decline

Thursday, April 2nd, 2015

The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

VICC’s Johnson to study cancer survivorship with immune inhibitor drugs

Thursday, March 19th, 2015

Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network  (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]

BlackHawk’s support reaches milestone

Thursday, February 12th, 2015

Country music group BlackHawk recently presented a check for $20,000 to Harold (Hal) Moses, M.D., Ingram Professor of Cancer Research and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), in support of cancer research. Since 2006, the group has raised and donated $100,000 to VICC in remembrance of one of the original members of the multi-platinum […]

Combo therapy may help fight melanoma

Thursday, January 8th, 2015

Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.

Indiana Couple Supports Melanoma Research

Thursday, October 16th, 2014

Vanderbilt-Ingram Cancer Center (VICC) melanoma patient Gerald (Jerry) Schreiber and wife Phyllis organized and hosted the first annual Melanoma Research Golf Classic in Evansville, Indiana. The golf scramble raised $19,000 for VICC melanoma research spearheaded by Igor Puzanov, M.D., MSCI, associate professor of Medicine and director of Melanoma Clinical Research.

Dermatology Adds New Treatments

Thursday, April 26th, 2012

Vanderbilt Dermatology has increased its ability to treat various forms of skin cancer, with the recent addition of a fifth Mohs surgeon and the approval of a new oral drug to treat the most severe cases of basal cell skin cancer. Preventing skin cancer, however, will always remain a focus. The Vanderbilt Mohs program became […]

Going for the Gold

Tuesday, April 17th, 2012

Vanderbilt-Ingram Cancer Center cordially invites you and your guests to join us for Going for the Gold: Living Well through Cancer! Due to an overwhelming response, we have closed registration. We are thrilled to have so many people attend! Date: Saturday, June 30, 2012 Time: 9:30 a.m.-2:30 p.m. Where: Vanderbilt University Student Life Center 310 […]

Melanoma Drug Risks Studied

Friday, March 23rd, 2012

Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]

Symposium set for Melanoma Survivors

Friday, March 2nd, 2012

Vanderbilt-Ingram Cancer Center melanoma experts will hold a patient education symposium for melanoma survivors and caregivers on Saturday, March 10, from 9:30 a.m. to 2:30 p.m. in the Preston Research Building, Room 898J. The free symposium, co-sponsored by the Melanoma Research Foundation, is open to all melanoma patients, no matter where they received their treatment. […]

Sosman Named to Melanoma ‘Dream Team’

Friday, December 16th, 2011

Jeffrey Sosman, M.D., professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA). Sosman is among the Dream Team’s principal investigators who will work closely to write the genomic-driven clinical trials and […]